Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus
NCT ID: NCT05922722
Last Updated: 2025-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2024-02-15
2025-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be asked to complete questionnaires that assess their understanding of the decision-making tool.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
NCT06161363
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
NCT05799378
The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS
NCT00413361
Covid-19 in Lupus Patients
NCT04355702
Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
NCT01551069
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study team members will study the data collected to answer research questions. They will analyze the data and plan better steps improve care quality in lupus.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with lupus
Decision-making tool
The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.
Questionnaire
Questionnaire to assess participant's understanding of the decision-making tool
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Decision-making tool
The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.
Questionnaire
Questionnaire to assess participant's understanding of the decision-making tool
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* validated SLE diagnosis
* no absolute contraindication to HCQ (e.g., retinopathy)
* prior HCQ therapy for at least 3-6 months
Exclusion Criteria
* participants who are not taking HCQ
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shivani Garg, MD, MS
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Protocol Version 5/23/23
Identifier Type: OTHER
Identifier Source: secondary_id
SMPH/MEDICINE/RHEUMATOL
Identifier Type: OTHER
Identifier Source: secondary_id
2023-0846
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.